Pharmacokinetics of drugs in cachectic patients: A systematic review

Katja Trobec; Mojca Kerec Kos; Stephan von Haehling; Jochen Springer; Stefan D. Anker; Mitja Lainscak

doi:10.1371/journal.pone.0079603

Pharmacokinetics of drugs in cachectic patients: A systematic review

Katja Trobec, Mojca Kerec Kos, Stephan von Haehling, Jochen Springer, Stefan D. Anker, Mitja Lainscak

Research output: Contribution to journal › Article › peer-review

84 Citations (SciVal)

Abstract

Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

Original language	English
Article number	e79603
Journal	PLoS One
Volume	8
Issue number	11
DOIs	https://doi.org/10.1371/journal.pone.0079603
Publication status	Published - 8 Nov 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0079603Licence: CC BY

Cite this

@article{fabf4b541c0149919e656a8eaf2ca089,

title = "Pharmacokinetics of drugs in cachectic patients: A systematic review",

abstract = "Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.",

author = "Katja Trobec and {Kerec Kos}, Mojca and {von Haehling}, Stephan and Jochen Springer and Anker, {Stefan D.} and Mitja Lainscak",

note = "{\textcopyright} 2013 Trobec et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2013",

month = nov,

day = "8",

doi = "10.1371/journal.pone.0079603",

language = "English",

volume = "8",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of drugs in cachectic patients: A systematic review

AU - Trobec, Katja

AU - Kerec Kos, Mojca

AU - von Haehling, Stephan

AU - Springer, Jochen

AU - Anker, Stefan D.

AU - Lainscak, Mitja

N1 - © 2013 Trobec et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2013/11/8

Y1 - 2013/11/8

N2 - Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

AB - Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

U2 - 10.1371/journal.pone.0079603

DO - 10.1371/journal.pone.0079603

M3 - Article

C2 - 24282510

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79603

ER -